Mebias Discovery holds a game-changing platform to discover next generation GPCR drugs devoid of on-target side effects once thought to be unavoidable.
We partner with investors to discover and progress pathway selective GPCR drugs.
Fully validated assay suite correlating ligand-induced dynamic conformation of GPCR to pathway-specific signaling.
Differentiated mu-opioid receptor drug candidates for the treatment of pain. br>
Seeking additional investors to collaborate and co-develop GPCR drugs without receptor associated side effects.